Development of the therapeutical strategy of inhibition of pancreatic fibrosis using Ptch1 peptide aiming improvement of immunotolerance in patients with pancreatic cancer

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K15593
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: General surgery
• Research Institution: Kyushu University
• Principal Investigator: Onishi Hideya 九州大学, 医学研究院, 准教授 (30553276)
• Co-Investigator(Kenkyū-buntansha): 中村 雅史 九州大学, 大学病院, 教授 (30372741) ; 中野 賢二 九州大学, 農学研究院, 特任教授 (00315061) ; 大内田 研宙 九州大学, 大学病院, 講師 (20452708) ; 山崎 章生 九州大学, 医学研究院, 共同研究員 (80404440)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: Ptch1ペプチド / Hedgehogシグナル / 膵癌 / 線維化 / リンパ球 / 免疫監視機構 / 癌浸潤リンパ球 / 抗腫瘍効果

Outline of Final Research Achievements

We used nude mice injected with mixture of pancreatic cancer cell line, ASPC-1 and cancer associated fibroblast subcutaneously. After tumor growing, activated lymphocytes were administrated intraperitoneally, and degree of fibrosis, tumor-infiltrated lymphocytes (TIL) number and tumor volume were estimated in control group and Ptch1 peptide group. Pancreatic fibrosis was reduced, TIL number was increased, and tumor volume was decreased in Ptch1 peptide group. These results suggest that Ptch1 peptide improves immunotolerance condition by decreasing pancreatic fibross and inducing TIL number.

Free Research Field

腫瘍免疫学